3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
Carboplatin
47
Etoposide
46
durvalumab
28
atezolizumab
28
Cisplatin
21
Topotecan
19
pembrolizumab
15
PM 01183
15
Nivolumab
12
Specimen Handling
11
anlotinib
9
Radiotherapy
9
Paclitaxel
9
Drug Therapy
9
Temozolomide
8
Magnetic Resonance Spectroscopy
8
AMG 757
8
Radiosurgery
7
Platinum
7
Irinotecan
7
toripalimab
6
olaparib
6
Biopsy
6
Ipilimumab
5
Injections
5
Docetaxel
5
Bevacizumab
5
trilaciclib
4
tremelimumab
4
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
lenvatinib
×
1 year
×
Clear all
NCT04938817
2026-06-01
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
110 enrolled
NCT04924101
2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2
Completed
126 enrolled